Extended thromboprophylaxis with betrixaban in acutely ill medical patients

Keyphrases

• Acute Disease 25%
• Acutely Ill Patients 100%
• Betrixaban 100%
• Between-group Difference 12%
• Confidence Interval 50%
• D-dimer 75%
• Efficacy Outcomes 37%
• Enoxaparin 62%
• Extended Duration 12%
• Extended Thromboprophylaxis 100%
• Large Cohort 12%
• Major Bleeding 25%
• No Significant Difference 12%
• Once-daily 25%
• Placebo 25%
• Population-based Cohort 12%
• Proximal Deep Vein Thrombosis 12%
• Recurrent Venous Thromboembolism 12%
• Relative Risk 50%
• Safety Outcomes 12%
• Sequential Analysis 12%
• Statistical Analysis Plan 12%
• Thromboprophylaxis 12%
• Venous Thrombosis 12%

Medicine and Dentistry

• Betrixaban 100%
• D-Dimer 37%
• Deep Vein Thrombosis 12%
• Disease 25%
• Major Bleeding 25%
• Phlebothrombosis 12%
• Placebo 25%
• Sequential Analysis 12%
• Thromboprophylaxis 100%
• Venous Thromboembolism 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Betrixaban 100%
• Bleeding 25%
• D Dimer 37%
• Deep Vein Thrombosis 12%
• Disease 25%
• Enoxaparin 62%
• Placebo 25%
• Vein Thrombosis 12%
• Venous Thromboembolism 12%